Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry. - Wikidata - wikimedia - TriplyDB

Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry.

Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry.

http://www.wikidata.org/entity/Q42143897

about

Phase II Study of Adjuvant Immunotherapy with the CSF-470 Vaccine Plus Bacillus Calmette-Guerin Plus Recombinant Human Granulocyte Macrophage-Colony Stimulating Factor vs Medium-Dose Interferon Alpha 2B in Stages IIB, IIC, and III Cutaneous Melanoma Data Independent Acquisition of HLA Class I Peptidomes on the Q Exactive Mass Spectrometer Platform.Deciphering HLA-I motifs across HLA peptidomes improves neo-antigen predictions and identifies allostery regulating HLA specificity.Tools to define the melanoma-associated immunopeptidome.Deciphering the MHC-associated peptidome: a review of naturally processed ligand data.The major histocompatibility complex class I immunopeptidome of extracellular vesicles.Next-Generation Sequencing to Guide Treatment of Advanced Melanoma.GibbsCluster: unsupervised clustering and alignment of peptide sequences.Applications of Immunogenomics to Cancer.Neoepitopes as cancer immunotherapy targets: key challenges and opportunities.Antigen Discovery and Therapeutic Targeting in Hematologic Malignancies.Secreted tumor antigens - immune biomarkers for diagnosis and therapy.Modified Vaccinia virus Ankara-based vaccines in the era of personalized immunotherapy of cancer.In silico and cell-based analyses reveal strong divergence between prediction and observation of T-cell-recognized tumor antigen T-cell epitopes.Mass spectrometry-based proteomic exploration of the human immune system: focus on the inflammasome, global protein secretion, and T cells.The Potential and Challenges of Exploiting the Vast But Dynamic Neoepitope Landscape for Immunotherapy.The SysteMHC Atlas project.Novel insights into the HLA class I immunopeptidome and T-cell immunosurveillance.'Hotspots' of Antigen Presentation Revealed by Human Leukocyte Antigen Ligandomics for Neoantigen Prioritization.Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens.Neoantigen prediction and the need for validation.Identification and Characterization of Neoantigens As Well As Respective Immune Responses in Cancer Patients.An Analysis of Natural T Cell Responses to Predicted Tumor Neoepitopes.The role of mass spectrometry and proteogenomics in the advancement of HLA epitope prediction.Neoantigen Targeting-Dawn of a New Era in Cancer Immunotherapy?Shared cancer neoantigens: Making private matters public.Informatics for cancer immunotherapy.MHC class I loaded ligands from breast cancer cell lines: A potential HLA-I-typed antigen collection.Specific Adoptive Cellular Immunotherapy in Allogeneic Stem Cell Transplantation.NetMHCpan-4.0: Improved Peptide-MHC Class I Interaction Predictions Integrating Eluted Ligand and Peptide Binding Affinity Data.Exploiting non-canonical translation to identify new targets for T cell-based cancer immunotherapy.HLA-A24 ligandome analysis of colon and lung cancer cells identifies a novel cancer-testis antigen and a neoantigen that elicits specific and strong CTL responses.The Potential of Donor T-Cell Repertoires in Neoantigen-Targeted Cancer Immunotherapy.Immunopharmacogenomics towards personalized cancer immunotherapy targeting neoantigens.High-throughput and Sensitive Immunopeptidomics Platform Reveals Profound Interferonγ-Mediated Remodeling of the Human Leukocyte Antigen (HLA) Ligandome.Predicted MHC peptide binding promiscuity explains MHC class I 'hotspots' of antigen presentation defined by mass spectrometry eluted ligand data.[Immunotherapy of cancer with checkpoint inhibitors : Not only in malignant melanoma].Targeting Neoantigens in Glioblastoma: An Overview of Cancer Immunogenomics and Translational Implications.Current Strategies to Enhance Anti-Tumour Immunity.Comprehensive immunoproteogenomic analyses of malignant pleural mesothelioma.

P2860

Q33741471-90632C62-04E1-4CC5-A105-776A9F86B2E2 Q38611717-5F61CF77-E31F-4922-8F0A-9E0BC2F061D9 Q38612613-972D9F82-857D-4744-BDD6-07F31EDB8DDF Q38650013-189396F4-21F0-4E2A-9BD5-85B396913E9E Q38653176-4056C8E4-EE25-4F12-B1CE-F7585EE5A390 Q38693646-29565CFA-7C3A-4D7E-9EF5-85C2785E10F6 Q38754313-F2FF0BCA-8FA0-41C4-BAF7-5D3DB4313D7A Q38838293-04E08B8B-AFF0-4CDF-90C0-90D0235057F7 Q39130420-15C534CF-3FEF-4E2D-833B-20B2BD4E0F0D Q39183391-4545CA31-381F-4F3D-8BE9-BBAC50939209 Q39243052-F706572A-897A-49E4-8DB9-0F8EB2AD9E1B Q39438407-F7477913-9981-41CC-9285-D8A2E94D8137 Q40068135-74641345-8C8E-4886-A80E-7809D2DD65CC Q40188864-C01997DE-34C6-44E7-8B12-2E6E6DCBAED7 Q40252565-0CE2E145-7A03-4521-9F89-8706E5228BFD Q41673084-55C95282-D2A3-4004-9203-333F0779DBCD Q41990341-82C903AA-37FB-4463-B3EF-77B5BBE0516A Q42346977-B77E0E4E-3BBE-422F-93D4-AD15ED20BD04 Q45718710-58E708E5-39F4-4631-B1A8-A714841FD2CD Q46398502-A49D4498-9EB3-4906-A392-C4EF1F668C42 Q46969749-9BC40BC0-0F21-46FE-AF02-B0E1E0B63D84 Q47133741-BD17DAA8-5642-48A8-A88F-94481CC2B4A0 Q47162995-1F4BB81E-DC12-434E-AA5D-0DAC9237F15E Q47190955-AEA05730-33CE-426F-896B-84CD459987EC Q47221163-924BA952-9ADD-451B-B792-4F0971C72FA0 Q47226691-633A1F0A-9C3F-4A3D-85B5-28BC4A9549F2 Q47290509-FD95C3FD-87B7-432E-8DF6-C181D8205CB0 Q47560871-9527DCDC-F07F-4C70-A88F-CBBF356277AF Q47566513-B20702C8-B13A-466D-BF24-497C7901D48D Q47696633-EC7E76DC-832F-4281-A850-AB786E08882F Q47797670-752106E6-1398-4AD5-918C-F5FCDCD3CAA2 Q47835567-ABE4D228-9395-4EF8-80FD-D14E5EF0BE07 Q49307766-F8AB8230-AB62-42D0-994F-8898C0BE83C0 Q49483662-D26CCE5E-64E8-4CC1-ACDD-D59E2125076E Q49836890-CAD623D2-5ADA-44F2-8B3C-442D29E940BD Q49990705-E142074E-C57D-46A9-B55A-D6D9CF3458D1 Q50034111-FC286000-DB91-464F-A05A-DB489E9B0CB8 Q50130464-7ED1B3A2-872B-434B-9DE0-CBE994C58E92 Q52344613-D6EF93BD-CD98-4BAC-A3FE-714D990648DE Q52606456-2103A6A5-1E4B-4570-847D-6D0A13E22BDF

P2860

Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry.

http://www.wikidata.org/entity/Q42143897

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Direct identification of clini ...... a tissue by mass spectrometry.

@en

Direct identification of clini ...... a tissue by mass spectrometry.

@nl

type

label

Direct identification of clini ...... a tissue by mass spectrometry.

@en

Direct identification of clini ...... a tissue by mass spectrometry.

@nl

prefLabel

Direct identification of clini ...... a tissue by mass spectrometry.

@en

Direct identification of clini ...... a tissue by mass spectrometry.

@nl

P1433

Q42143897-A4CF985C-9436-4406-87BA-F2F2CB042160

P1476

Q42143897-1C20E3D8-1ADA-4173-BDC9-DF0BF72A54C7

P2093

Q42143897-1899AD53-0134-4C72-A7C5-9312B2934C03

Q42143897-231BAC2B-A703-4E81-B967-4E73552575BB

Q42143897-2481A750-0ED9-4E87-9B50-2678D8C12581

Q42143897-2D968402-E066-4886-A572-E6435DE42C0C

Q42143897-2E46B30F-B0B5-42B2-84EE-3058B08873AF

Q42143897-3923A432-3ED9-4A97-A942-F2DACE564942

Q42143897-5766B29E-5F1C-4B47-9AAA-EA4E56E93889

Q42143897-73FD9B83-7412-4D92-8EE1-03959F9D5F49

Q42143897-938A2785-439E-4564-9BCA-FEC3C688B05F

Q42143897-96CE6952-E25D-4502-8704-BD3253457053

P2860

Q42143897-021FD32B-200B-4CF4-B291-BEDEC456BEA1

Q42143897-09AC3EA6-C3F8-49A8-BF54-27D3C794A83E

Q42143897-0C1B97AE-B10E-41CE-BB2E-FFE8F3B8D108

Q42143897-186304E3-3BD8-48CB-908F-070CCB8F19AA

Q42143897-1DE84C27-DE4C-410E-9698-BE28083CD51A

Q42143897-1EB52290-A4C9-45B0-999A-C2261F35F3D6

Q42143897-223EF7C1-3379-4DC2-A2F6-D53C56D99D96

Q42143897-26622DF2-40C7-4331-AB63-B18DB8B35933

Q42143897-27592567-0322-436A-AB56-98EA2725CC61

Q42143897-277AEB66-DD18-4F14-87B9-6AF3B68D0EA8

P2888

Q42143897-18C62E03-C79E-4476-AC1D-9343D3413FDA

P304

Q42143897-A559568D-67D1-4A25-8FA6-902C995D8B47

P31

Q42143897-C1653230-CC62-49D3-8A51-699A897C1E6E

P356

Q42143897-3C11D7C7-5D73-4DDB-8EEF-AC7AE43246C2

P407

Q42143897-329D3179-DC5C-41FD-BC43-3D864F8A3243

P478

Q42143897-07544DF8-9B3E-4154-8148-B6FF9699D81E

P50

Q42143897-267F7D23-ED58-4AB3-9383-850D2E8C6C5B

Q42143897-2B85C323-A626-43AB-A8C4-79659A2F5FD0

P577

Q42143897-BB61FB93-6C99-43EF-8996-BF94736FBCF6

P698

Q42143897-C1653F95-9516-4CC7-9442-C30CBAE7E26F

P932

Q42143897-D88C9BCB-20E9-446E-B846-D183307872E0

P356

P1433

Nature Communications

P1476

Direct identification of clini ...... a tissue by mass spectrometry.

@en

P2093

Angela M Krackhardt

http://www.w3.org/2001/XMLSchema#string

Angelika Werner

http://www.w3.org/2001/XMLSchema#string

Christian Peschel

http://www.w3.org/2001/XMLSchema#string

Dirk H Busch

http://www.w3.org/2001/XMLSchema#string

Eva Bräunlein

http://www.w3.org/2001/XMLSchema#string

Julia Slotta-Huspenina

http://www.w3.org/2001/XMLSchema#string

Julia Weber

http://www.w3.org/2001/XMLSchema#string

Jürgen Cox

http://www.w3.org/2001/XMLSchema#string

Katja Specht

http://www.w3.org/2001/XMLSchema#string

Marc E Martignoni

http://www.w3.org/2001/XMLSchema#string

P2860

The response of autologous T cells to a human melanoma is dominated by mutated neoantigens

Fast and accurate short read alignment with Burrows-Wheeler transform

Cancer regression in patients after transfer of genetically engineered lymphocytes

Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method

Phosphorylation-dependent interaction between antigenic peptides and MHC class I: a molecular basis for the presentation of transformed self

The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Pinning down proline-directed phosphorylation signaling

PhosphoSitePlus, 2014: mutations, PTMs and recalibrations

Signatures of mutational processes in human cancer

P2888

P304

13404

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NCOMMS13404

http://www.w3.org/2001/XMLSchema#string

P407

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Michal Bassani-Sternberg

P577

2016-11-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27869121

http://www.w3.org/2001/XMLSchema#string

P932

5121339

http://www.w3.org/2001/XMLSchema#string